Rasagiline [(R)-N-(prop-2-yn-1-yl)-2,3-di­hydro-1H-inden-1-amine, C12H13N, see Fig. 1 ▸] is an oral, second-generation, selective, irreversible mono­amine oxidase B (MAO-B) inhibitor used for the treatment of Parkinson’s disease and as an adjunct therapy to levodopa in more advanced cases, approved in the USA and EU. This evidence concerns the gene MAOB and Parkinson disease.